BNP Paribas Financial Markets Has $1.08 Million Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

BNP Paribas Financial Markets lifted its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 110.1% in the third quarter, HoldingsChannel reports. The institutional investor owned 72,963 shares of the medical research company’s stock after buying an additional 38,238 shares during the period. BNP Paribas Financial Markets’ holdings in NeoGenomics were worth $1,076,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NEO. Blue Trust Inc. boosted its stake in shares of NeoGenomics by 107.2% during the 2nd quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after buying an additional 1,206 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of NeoGenomics during the 2nd quarter worth about $57,000. KBC Group NV boosted its stake in shares of NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after buying an additional 1,127 shares during the last quarter. FMR LLC boosted its stake in shares of NeoGenomics by 7.6% during the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock worth $196,000 after buying an additional 931 shares during the last quarter. Finally, Banque Cantonale Vaudoise boosted its stake in shares of NeoGenomics by 10.2% during the 2nd quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock worth $244,000 after buying an additional 1,633 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Trading Up 2.9 %

Shares of NEO stock opened at $18.43 on Wednesday. The firm has a 50 day moving average price of $15.16 and a two-hundred day moving average price of $15.06. The company has a quick ratio of 1.91, a current ratio of 1.99 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $2.37 billion, a PE ratio of -30.21 and a beta of 1.24. NeoGenomics, Inc. has a 12-month low of $12.77 and a 12-month high of $21.22.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.04. The firm had revenue of $167.80 million during the quarter, compared to the consensus estimate of $167.00 million. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period last year, the business posted ($0.06) earnings per share. As a group, analysts predict that NeoGenomics, Inc. will post -0.17 earnings per share for the current year.

Insiders Place Their Bets

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $15.36, for a total value of $79,488.00. Following the completion of the sale, the general counsel now directly owns 37,129 shares in the company, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

NEO has been the subject of a number of research analyst reports. Benchmark reiterated a “buy” rating and set a $18.00 price target on shares of NeoGenomics in a report on Tuesday, September 24th. Needham & Company LLC reiterated a “buy” rating and set a $19.00 price target on shares of NeoGenomics in a report on Wednesday, November 6th. Finally, Jefferies Financial Group initiated coverage on NeoGenomics in a report on Tuesday. They set a “buy” rating and a $22.00 price target for the company. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $20.44.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.